Amicus Therapeutics (FOLD) Scheduled to Post Quarterly Earnings on Thursday

Amicus Therapeutics (NASDAQ:FOLD) is set to issue its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect Amicus Therapeutics to post earnings of ($0.06) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. The company had revenue of $115.08 million for the quarter, compared to analyst estimates of $115.11 million. On average, analysts expect Amicus Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Amicus Therapeutics Trading Up 0.8 %

Shares of FOLD opened at $10.42 on Wednesday. The stock’s 50-day moving average price is $11.41 and its 200 day moving average price is $11.99. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 2.42. The firm has a market capitalization of $3.09 billion, a price-to-earnings ratio of -20.43 and a beta of 0.80. Amicus Therapeutics has a 12-month low of $9.70 and a 12-month high of $14.57.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 4,167 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $14.00, for a total transaction of $58,338.00. Following the transaction, the chief executive officer now owns 871,219 shares of the company’s stock, valued at $12,197,066. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Bradley L. Campbell sold 4,167 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $58,338.00. Following the completion of the sale, the chief executive officer now directly owns 871,219 shares of the company’s stock, valued at $12,197,066. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David Michael Clark sold 4,427 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $61,978.00. Following the completion of the transaction, the insider now owns 253,664 shares in the company, valued at $3,551,296. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 55,208 shares of company stock worth $732,930. Insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on FOLD shares. Cantor Fitzgerald restated an “overweight” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a research note on Thursday, February 29th. JPMorgan Chase & Co. decreased their price objective on Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday, March 18th.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.